Compare CTRI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | ADPT |
|---|---|---|
| Founded | 1909 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2024 | 2019 |
| Metric | CTRI | ADPT |
|---|---|---|
| Price | $28.44 | $18.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $26.40 | $16.60 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $2,841,255,000.00 | $252,754,000.00 |
| Revenue This Year | $10.65 | $50.86 |
| Revenue Next Year | $9.36 | $0.53 |
| P/E Ratio | $1,124.92 | ★ N/A |
| Revenue Growth | 9.89 | ★ 42.57 |
| 52 Week Low | $14.46 | $6.26 |
| 52 Week High | $28.89 | $20.76 |
| Indicator | CTRI | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 70.51 | 59.49 |
| Support Level | $26.49 | $16.55 |
| Resistance Level | $28.75 | $19.16 |
| Average True Range (ATR) | 1.02 | 1.00 |
| MACD | 0.09 | 0.18 |
| Stochastic Oscillator | 87.97 | 82.08 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. It operates under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).